Zobrazeno 1 - 10
of 512
pro vyhledávání: '"Ting, Niu"'
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-37 (2024)
Abstract Hemophagocytic lymphohistiocytosis (HLH) is a rapidly progressing, life-threatening syndrome characterized by excessive immune activation, often presenting as a complex cytokine storm. This hyperactive immune response can lead to multi-organ
Externí odkaz:
https://doaj.org/article/534f596f57ed463584a9efc28b43e986
Autor:
Sanfang Tu, Xiu Luo, Heng Mei, Yongxian Hu, Yang Liu, Ping Li, Dehui Zou, Ting Niu, Kailin Xu, Xi Zhang, Lugui Qiu, Lei Gao, Guangxun Gao, Li Zhang, Yimei Feng, Ying Wang, Mingfeng Zhao, Jianqing Mi, Ming Hou, Jianmin Yang, He Huang, Jianxiang Wang, Yu Hu, Weili Zhao, Depei Wu, Jun Ma, Yuhua Li, Wenbin Qian, Xiaojun Huang, Weidong Han, Aibin Liang, Yanjie Yin
Publikováno v:
Chinese Medical Journal, Vol 137, Iss 22, Pp 2681-2683 (2024)
Externí odkaz:
https://doaj.org/article/7d619e531cdd41f1a9d3f79c5299338b
Autor:
Yu Feng, Hongmei Luo, Jingcao Huang, Yue Zhang, Jingjing Wen, Linfeng Li, Ziyue Mi, Qianwen Gao, Siyao He, Xiang Liu, Xinyu Zhai, Xin Wang, Li Zhang, Ting Niu, Yuhuan Zheng
Publikováno v:
Cell Death and Disease, Vol 15, Iss 8, Pp 1-11 (2024)
Abstract Proteasome inhibitors (PIs), such as bortezomib and calfizomib, were backbone agents in the treatment of multiple myeloma (MM). In this study, we investigated bortezomib interactors in MM cells and identified dihydrolipoamide dehydrogenase (
Externí odkaz:
https://doaj.org/article/d912089c4f09434995cd15f9eafcb550
Autor:
Kai Shen, Jie Huang, Chenlu Yang, Xiao Shuai, Yong Guo, Liping Xie, Jianjun Li, Yongqian Jia, Yuping Gong, Ting Niu, Hongbing Ma
Publikováno v:
Therapeutic Advances in Hematology, Vol 15 (2024)
Background: All-trans retinoic acid (ATRA) and arsenic trioxide (ATO) have revolutionized the treatment of acute promyelocytic leukemia (APL). However, the management of high-risk APL has not been conclusively established. The optimal dosage of anthr
Externí odkaz:
https://doaj.org/article/6366df56d2904d19a4c6a55d31460fee
Publikováno v:
Molecular Biomedicine, Vol 5, Iss 1, Pp 1-32 (2024)
Abstract Multiple myeloma (MM) is the second most common hematological malignancy of plasma cells, characterized by osteolytic bone lesions, anemia, hypercalcemia, renal failure, and the accumulation of malignant plasma cells. The pathogenesis of MM
Externí odkaz:
https://doaj.org/article/e7a61a64e6324c728565b80297ff6fec
Autor:
Mengshi Hu, Tao Yang, Linyu Yang, Lu Niu, Jinbing Zhu, Ailin Zhao, Mingsong Shi, Xue Yuan, Minghai Tang, Jianhong Yang, Heying Pei, Zhuang Yang, Qiang Chen, Haoyu Ye, Ting Niu, Lijuan Chen
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-4 (2024)
Externí odkaz:
https://doaj.org/article/6aeb2b5162d94e52bba8affde5d0b2f5
Autor:
Zhixiong Zhu, Hexian Li, Qizhong Lu, Zongliang Zhang, Jia Li, Zeng Wang, Nian Yang, Zhengyu Yu, Chen Yang, Yongdong Chen, Huaqing Lu, Wei Wang, Ting Niu, Chunlai Nie, Aiping Tong
Publikováno v:
Advanced Science, Vol 11, Iss 35, Pp n/a-n/a (2024)
Abstract Clinical trials of Chimeric Antigen Receptor T‐cell (CAR‐T) therapy have demonstrated remarkable success in treating both solid tumors and hematological malignancies. Nanobodies (Nbs) have emerged as promising antigen‐targeting domains
Externí odkaz:
https://doaj.org/article/8b15ce605dcc484b9a66e75fbf9aa14f
Publikováno v:
Cancer Medicine, Vol 13, Iss 17, Pp n/a-n/a (2024)
Abstract Background Chromosomal 1q gains and amplifications (+1q21) are frequently observed in patients with newly diagnosed multiple myeloma (NDMM). However, the interpretation of the high‐risk (HR) prognostic implications stemming from 1q21 abnor
Externí odkaz:
https://doaj.org/article/ca0d0a9f5e71453886a51b2dbf53e30d
Autor:
Ming-Ci Cai, Shu Cheng, Hong-Mei Jing, Yan Liu, Guo-Hui Cui, Ting Niu, Jian-Zhen Shen, Liang Huang, Xin Wang, Yao-Hui Huang, Li Wang, Peng-Peng Xu, Wei-Li Zhao
Publikováno v:
The Lancet Regional Health. Western Pacific, Vol 50, Iss , Pp 101160- (2024)
Summary: Background: Peripheral T-cell lymphoma (PTCL) is a heterogeneous disease with dismal outcomes. We conducted an open-label, phase 2 nonrandomised, externally controlled study to evaluate the efficacy and safety of targeted agents plus CHOP (c
Externí odkaz:
https://doaj.org/article/7de9b0251dbf4d408a2dc6d1d4a01309
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 30 (2024)
A new scoring system termed sepsis-induced coagulopathy (SIC) has been proposed to diagnose early sepsis-induced disseminated intravascular coagulation (DIC). This study performed DIC-related analyses in patients with confirmed SIC. Data from the int
Externí odkaz:
https://doaj.org/article/731fae1a93b84acca89341091aa435ac